Suneet Varma, a former senior executive at Pfizer, has taken the CEO position at Intent Biologics, a new biotech company focused on inflammation and immunology.
Intent Biologics is a newly created company and is described as "phase 3-ready," indicating it has a lead program prepared to enter late-stage (phase 3) clinical trials.
The company operates in the regenerative medicine space, emphasizing therapies aimed at repairing or replacing damaged cells or tissues.
Varma’s leadership experience at Pfizer is a key asset for Intent Biologics as it advances its development pipeline.
The move was reported on September 9, 2025, and is regarded as significant news in the biotech sector for the leadership and late-stage readiness of Intent Biologics.25
Sources:
2. https://www.fiercebiotech.com
5. https://www.fiercebiotech.com/biotech/pfizer-vet-takes-ceo-post-new-phase-3-ready-regenerative-medicine-biotech